The IL-33/ST2 signaling pathway is involved in various adverse pathophysiological processes after infarction, such as fibrosis, inflammation, and hypertrophy, which are important targets for a variety of neuroendocrine antagonists currently available to improve the prognosis of MI patients. This evidence concerns the gene IL1RL1 and myocardial infarction.